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Background. Patterns of cause-specific mortality in individuals infected with human immunodeficiency virus
type 1 (HIV-1) are changing dramatically in the era of antiretroviral therapy (ART).
Methods. Sixteen cohorts from Europe and North America contributed data on adult patients followed from the
start of ART. Procedures for coding causes of death were standardized. Estimated hazard ratios (HRs) were adjusted
for transmission risk group, sex, age, year of ART initiation, baseline CD4 count, viral load, and AIDS status, before
and after the first year of ART.
Results. A total of 4237 of 65 121 (6.5%) patients died (median, 4.5 years follow-up). Rates of AIDS death decreased
substantially with time since starting ART, but mortality from non-AIDS malignancy increased (rate ratio, 1.04 per year;
95% confidence interval [CI], 1.0–1.1). Higher mortality in men than women during the first year of ART was mostly
due to non-AIDS malignancy and liver-related deaths. Associations with age were strongest for cardiovascular disease,
heart/vascular, andmalignancy deaths. Patients with presumed transmission through injection drug use had higher rates
of all causes of death, particularly for liver-related causes (HRs compared with men who have sex with men: 18.1 [95%
CI, 6.2–52.7] during the first year of ART and 9.1 [95% CI, 5.8–14.2] thereafter). There was a persistent role of CD4
count at baseline and at 12 months in predicting AIDS, non-AIDS infection, and non-AIDS malignancy deaths. Lack of
viral suppression on ART was associated with AIDS, non-AIDS infection, and other causes of death.
Conclusions. Better understanding of patterns of and risk factors for cause-specific mortality in the ARTera can aid
in development of appropriate care for HIV-infected individuals and inform guidelines for risk factor management.
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Antiretroviral therapy (ART) has dramatically reduced mortal-
ity for people living with human immunodeficiency virus
(HIV), or PLWH, allowing life expectancy for those successfully
treated to approach that of the general population [1–3]. How-
ever, overall mortality among PLWH remains higher than in the
general population [4–6]. As the HIV-infected population ages
and duration on ART increases, the distribution of causes of
death and associations with patient characteristics are changing.
The proportion of AIDS-related deaths in PLWH has decreased
in the ART era [7, 8], and decreases with duration on ART [9].
In high-income countries, there is concern over excess mortality
from cancer [6, 10–12] and cardiovascular disease (CVD) [6].
Appropriate management of HIV disease and associated co-
morbidities may result in further decreases in mortality, but
will depend on a detailed understanding of causes of death.
Based on a large collaboration of cohorts of PLWH in whom
causes of death were classified according to standardized proce-
dures, we assessed how patterns of causes of death change with
time since starting ART. We estimated associations of patient
characteristics with specific causes of death in the first year
after starting ART and in subsequent years.
METHODS
Cohorts and Patients
The Antiretroviral Therapy Cohort Collaboration (ART-CC) is
a collaboration of cohort studies of PLWH from Europe and
North America [13] (available at: http://www.bris.ac.uk/art-cc).
Prospective cohorts were eligible if they had enrolled at least
100 HIV type 1 (HIV-1)–infected patients aged ≥16 years
who were not previously exposed to antiretroviral drugs and
started ART with at least 3 drugs, including nucleoside reverse
transcriptase inhibitors, protease inhibitors, or nonnucleoside
reverse transcriptase inhibitors, with a median follow-up of
≥1 year. All cohorts use quality control procedures. The data-
base was updated in September 2010. Institutional review
boards approved data collection at all sites according to local re-
quirements. The National Health Service Health Research Au-
thority South West–Cornwall and Plymouth Research Ethics
Committee, United Kingdom, has approved the ART-CC
study (REC reference 12/SW/0253).
Coding Causes of Death
Information on cause of death was recorded by 16 cohorts (Ap-
pendix) either as International Classification of Diseases, Ninth
Revision (ICD-9) or Tenth Revision (ICD-10), Classification
based on the Coding of Death in HIV (CoDe) project (available
at: http://www.chip.dk/CoDe/tabid/55/Default.aspx), or free
text. We adapted the CoDe protocol [14] to classify causes of
death into mutually exclusive categories. Clinicians classified
deaths using summary tables of patient details that included
ICD-9/ICD-10 codes or free text for cause of death, patient char-
acteristics at ART initiation (age, sex, transmission risk group,
AIDS-defining conditions, and hepatitis C status), time from
ART initiation to death, AIDS-defining conditions after starting
ART, latest CD4 (within 6 months of death), and whether a pa-
tient was on ART at time of death. A computer algorithm devel-
oped by the Mortalité 2000–2005 Study Group [15] classified
deaths using ICD-10 codes, when available. When ICD-10
codes were not available, 2 clinicians independently classified each
death. Disagreements between clinicians and/or computer-
assigned codes were resolved via panel discussion as per the
CoDe protocol described previously [9]. Further information on
rules to classify deaths is provided in the Supplementary Data.
We grouped causes of death with a frequency of <20 as
“other.” AIDS was defined according to the 1993 Centers for
Disease Control and Prevention classification [16] and included
CoDe 01 (unspecified AIDS), 01.1 (AIDS infection), and 01.2
(AIDS malignancy). We grouped deaths as AIDS, non-AIDS in-
fection, liver-related (hepatitis and liver failure, CoDe 03 and
14), non-AIDS nonhepatitis malignancy (CoDe 04), cardiovas-
cular disease (myocardial infarction/ischemic heart disease,
CoDe 08, and stroke, CoDe 09), heart/vascular disease (heart
failure/unspecified, and other heart disease, CoDe 24), respira-
tory disease (chronic obstructive lung disease, CoDe 13 and 25),
renal failure (CoDe 15), disease of the central nervous system
(CoDe 23), unnatural deaths (accident/violent, suicide, and
overdose, CoDe 16, 17, and 19), and other (CoDe 90).
Statistical Analysis
Follow-up time was calculated from date of starting ART
(“baseline”) to the earliest of death, last clinic follow-up plus
3 months (because cohorts scheduled visits every 6 months
and therefore using the last clinic follow-up date would under-
estimate follow-up time), or cohort-specific administrative cen-
soring date (“database close”). Crude mortality rates for each
cause of death were compared for all patients and by time
since starting ART (<0.5, 0.5–0.99, 1–1.99, 2–4.99, and 5–10
years). Crude hazard ratios (HRs) were derived according to
age, baseline CD4 count, and risk group. Median CD4 count
at death (interquartile range [IQR]) was calculated for each
cause of death. To investigate changes in patterns of cause of
death over time, and to avoid violation of the proportional haz-
ards assumption, separate Cox models were used to estimate
HRs in the first year of ART and in subsequent years. Models
were adjusted for sex, risk group (men who have sex with
men [MSM], injection drug users [IDUs], heterosexuals, and
other [includes transmission through blood or other unknown
routes]), current age (per decade), baseline CD4 count (<50,
50–99, 100–199, 200–349, ≥350 cells/µL), baseline viral load
(<100 000 copies, ≥100 000 copies), AIDS prior to ART, and
year of ART initiation (1996–1999, 2000–2003, 2004–2009),
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stratified by cohort. HRs after the first year were adjusted for 12-
month CD4 count and viral load (closest measure to 12 months
after ART start, within ±3 months) and for AIDS status at 12
months. Patients were classified as having AIDS at 12 months
if they had an AIDS diagnosis any time up to 12 months after
ART start. Analyses were repeated accounting for competing
risks using the method of Fine and Gray [17].
RESULTS
Of 65 121 patients followed up between 1996 and 2009, 4237
(6.5%) died during 327 535 person-years of follow-up (median,
4.5 years [IQR, 2.0–7.8]), giving a mortality rate of 12.9 deaths
per 1000 person-years (95% confidence interval [CI], 12.6–
13.3). A total of 1225 (28.9%) deaths occurred in the first year
of ART mortality rate 20.0 per 1000 person-years (95% CI,
18.9–21.2) and 3012 (71.1%) after the first year mortality rate
11.3 per 1000 person-years (95% CI, 10.9–11.7). Specific
cause of death was classifiable for 3574 (84.4%) deaths (1057
in the first year and 2517 after). Compared with patients
whose deaths were classified, those with unclassifiable deaths
were older, had higher baseline CD4 and lower viral load. A
total of 1496 (41.9%) of the classified deaths were due to
AIDS (AIDS infection: 557, nonspecific AIDS: 550, AIDS ma-
lignancy: 389), 461 (12.9%) to non-AIDS malignancy, and 349
(9.8%) to unnatural causes. Patients were lost to follow-up if
they had no visit recorded in the year prior to database close.
Of 65 121 patients, 23 794 were lost to follow-up (4813 in the
first year since ART initiation and 18 981 in subsequent
years), giving a rate of 7.26 per 100 person-years (95% CI,
7.17–7.36), ranging from 2.02 to 10.39 across cohorts. Com-
pared with patients remaining in care, those lost to follow-up
were younger, more likely to be IDUs, initiated in earlier
years, and had higher baseline CD4 and lower viral load.
Table 1 shows patient characteristics at baseline, overall and
according to whether death was AIDS or non-AIDS related. The
majority of patients were male and infected through sexual con-
tact. Median age was 37 years (IQR, 31–44 years), the median
CD4 count was 217 cells/µL (IQR, 96–340), and the median
viral load was 70 000 copies/mL (IQR, 14 000–213 684). A
total of 14 202 patients (21.8%) had an AIDS diagnosis before
ART. Compared with patients who died of AIDS, those who
died from non-AIDS causes were older, were more likely to
be IDUs, had higher baseline CD4 count and lower viral load,
and were less likely to have AIDS prior to ART.
Table 2 shows rates of causes of death for all patients, and
numbers of deaths and crude HRs according to baseline CD4
(<200 vs ≥200 cells/µL), age (<60 vs ≥60 years), and transmis-
sion risk group. The rate of AIDS death was 4.6 (95% CI, 4.3–
4.8) per 1000 person-years. Patients with baseline CD4 count
≥200 cells/µL experienced lower rates of each cause of death
than those with baseline CD4 count <200 cells/µL, except for
unnatural causes and suicide. Rates of cause-specific mortality
were higher among older than younger patients, except for un-
natural and liver-related deaths. The higher rate of liver-related
deaths in younger patients may be explained by the higher pro-
portion of IDUs in this group. Older people had higher rates of
malignancy and CVD. Rates for MSM and heterosexuals were
broadly similar, although MSM had a higher rate of AIDS ma-
lignancy. Patients with presumed transmission via injection
drug use had higher rates of all causes of death than other
Table 1. Patient Characteristics at Antiretroviral Therapy Start for











Male 46 798 (71.9) 1702 (81.9) 1175 (78.5)
Female 18 323 (28.1) 376 (18.1) 321 (21.5)
Age, y
16–29 12 322 (18.9) 158 (7.6) 190 (12.7)
30–39 27 682 (42.5) 754 (36.3) 600 (40.1)
40–49 16 407 (25.2) 628 (30.2) 401 (26.8)
50–59 6339 (9.7) 348 (16.8) 200 (13.4)
≥60 2371 (3.6) 190 (9.1) 105 (7.0)
Transmission risk group
MSM 21 177 (32.5) 482 (23.2) 392 (26.2)
IDU 10 396 (16.0) 724 (34.8) 348 (23.3)
Heterosexual 26 668 (41.0) 592 (28.5) 458 (30.6)
Other 6880 (10.6) 280 (13.5) 298 (19.9)
CD4 at ART start, cells/µL
<50 10 210 (15.7) 432 (20.8) 602 (40.2)
50–99 6462 (9.9) 274 (13.2) 256 (17.1)
100–199 13 106 (20.1) 459 (22.1) 299 (20.0)
200–349 19 971 (30.7) 513 (24.7) 231 (15.4)
≥350 15 372 (23.6) 400 (19.3) 108 (7.2)
Viral load at ART start, copies/mL
<10 000 14 157 (21.7) 341 (16.4) 194 (13.0)
10 000–
99 999
23 600 (36.2) 664 (32.0) 401 (26.8)
≥100 000 27 364 (42.0) 1073 (51.6) 901 (60.2)
AIDS diagnosis at ART start
No AIDS 50 919 (78.2) 1491 (71.7) 705 (47.1)
AIDS 14 202 (21.8) 587 (28.3) 791 (52.9)
Period of ART initiation
1996–1999 19 720 (30.3) 1065 (51.3) 687 (45.9)
2000–2003 22 528 (34.6) 691 (33.3) 535 (35.8)
2004–2009 22 873 (35.1) 322 (15.5) 274 (18.3)
Data are presented as No. (%).
Abbreviations: ART, antiretroviral therapy; IDU, injection drug user; MSM, men
who have sex with men.
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Table 2. Crude Cause-Specific Mortality Rates per 1000 Person-years and Numbers of Deaths, Stratified by Baseline CD4, Age, and Transmission Risk Group
All Patients







Cause of Death No. Rate No. No. HR No. No. HR No. No. HR No. HR
All causes 4237 12.9 (12.6–13.3) 2722 1515 0.5 (.4–.5) 3873 364 2.9 (2.6–3.2) 1037 1247 2.4 (2.2–2.6) 1247 1.0 (.9–1.1)
AIDS 1496 4.6 (4.3–4.8) 1157 339 0.2 (.2–.3) 1391 105 2.2 (1.8–2.7) 392 348 1.8 (1.6–2.1) 458 1.0 (.8–1.1)
AIDS (nonspecific) 550 1.7 (1.5–1.8) 428 122 0.2 (.2–.3) 501 49 3.0 (2.2–4.0) 119 176 3.0 (2.4–3.8) 169 1.2 (.9–1.5)
AIDS infection 557 1.7 (1.6–1.8) 457 100 0.2 (.1–.2) 530 27 1.5 (1.0–2.2) 113 126 2.3 (1.7–2.9) 193 1.4 (1.1–1.8)
AIDS malignancy 389 1.2 (1.1–1.3) 272 117 0.4 (.3–.4) 360 29 2.3 (1.6–3.4) 160 46 0.6 (.4–.8) 96 0.5 (.4–.6)
Non-AIDS 2078 6.3 (6.1–6.6) 1165 913 0.6 (.6–.7) 1888 190 3.2 (2.7–3.7) 482 724 3.0 (2.7–3.4) 592 1.1 (.9–1.2)
Malignancy (non-AIDS nonhepatitis) 461 1.4 (1.3–1.5) 266 195 0.6 (.5–.7) 406 55 4.4 (3.3–5.8) 147 91 1.2 (1.0–1.6) 174 1.0 (.8–1.3)
Infection 314 1.0 (.9–1.1) 208 106 0.4 (.3–.5) 286 28 3.0 (2.1–4.5) 51 109 4.3 (3.1–6.0) 99 1.7 (1.2–2.3)
Liver related (all, includes liver cancer) 302 0.9 (.8–1.0) 172 130 0.6 (.5–.8) 296 6 0.6 (.3–1.4) 35 184 10.6 (7.4–15.2) 51 1.2 (.8–1.9)
Hepatitis 222 0.7 (.6–.8) 129 93 0.6 (.4–.8) 219 3 0.4 (.1–1.4) 19 161 17.0 (10.6–27.4) 21 1.0 (.5–1.8)
Liver failure 80 0.2 (.2–.3) 43 37 0.7 (.5–1.1) 77 3 1.2 (.4–3.8) 16 23 2.9 (1.5–5.5) 30 1.6 (.9–2.9)
CVD 160 0.5 (.4–.6) 83 77 0.7 (.5–1.0) 127 33 8.3 (5.7–12.2) 53 27 1.0 (.6–1.6) 49 0.8 (.5–1.2)
MI/IHD 106 0.3 (.3–.4) 55 51 0.7 (.5–1.1) 86 20 7.4 (4.6–12.1) 40 21 1.1 (.6–1.8) 25 0.5 (.3–.9)
Stroke 54 0.2 (.1–.2) 28 26 0.7 (.4–1.3) 41 13 10.2 (5.4–19.0) 13 6 0.9 (.4–2.4) 24 1.6 (.8–3.1)
Heart/vascular 131 0.4 (.3–.5) 75 56 0.6 (.4–.8) 115 16 4.3 (2.6–7.3) 28 43 3.1 (1.9–5.0) 41 1.3 (.8–2.0)
Unnatural (all) 349 1.1 (1.0–1.2) 147 202 1.1 (.9–1.4) 339 10 0.9 (.5–1.7) 80 164 4.1 (3.2–5.4) 57 0.6 (.4–.9)
Suicide 97 0.3 (.2–.4) 32 65 1.6 (1.1–2.5) 95 2 0.7 (.2–2.7) 43 27 1.3 (.8–2.0) 20 0.4 (.2–.7)
Substance abuse 191 0.6 (.5–.7) 85 106 1.0 (.8–1.3) 186 5 0.8 (.3–2.0) 18 117 13.1 (8.0–21.5) 27 1.3 (.7–2.3)
Other violent 61 0.2 (.1–.2) 30 31 0.8 (.5–1.4) 58 3 1.6 (.5–5.2) 19 20 2.1 (1.1–4.0) 10 0.5 (.2–1.0)
Respiratory 61 0.2 (.1–.2) 33 28 0.7 (.4–1.1) 49 12 7.9 (4.2–14.9) 15 19 2.5 (1.3–5.0) 20 1.2 (.6–2.3)
Renal 37 0.1 (.1–.2) 30 7 0.2 (.1–.4) 31 6 6.0 (2.5–14.5) 5 4 1.6 (.4–6.0) 17 2.9 (1.1–7.9)
CNS 41 0.1 (.1–.2) 30 11 0.3 (.1–.6) 37 4 3.3 (1.2–9.3) 14 11 1.6 (.7–3.5) 8 0.5 (.2–1.2)
Otherb 222 0.7 (.6–.8) 121 101 0.7 (.5–.9) 202 20 3.1 (2.0–5.0) 54 72 2.7 (1.9–3.8) 76 1.2 (.9–1.7)
Unknown 663 2.0 (1.9–2.2) 400 263 0.5 (.5–.6) 594 69 3.6 (2.8–4.6) 163 175 2.2 (1.7–2.7) 197 1.0 (.8–1.3)
Ranges in parentheses are 95% confidence intervals.
Abbreviations: CNS, central nervous system; CVD, cardiovascular disease; HR, hazard ratio; IDU, injection drug user; IHD, ischaemic heart disease; MI, myocardial infarction; MSM, men who have sex with men.
a Baseline category for comparison.
b
“Other” deaths were diabetes (5), pancreatitis (6), lactic acidosis (11), gastrointestinal hemorrhage (18), pulmonary hypertension (4), lung embolus (18), euthanasia (1), hematological (14), psychiatric (8), digestive (16),
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risk groups, particularly deaths from infection, liver disease, and
substance abuse.
Figure 1 shows rates of selected causes of death by time since
starting ART. All-cause mortality rates decreased from 24.3
(95% CI, 22.7–26.1) per 1000 person-years in the first 6 months
of ART to 10.2 (95% CI, 9.6–10.9) after 5 years. This was largely
due to substantial decreases in AIDS-related death, from 13.2
(95% CI, 12.0–14.5) per 1000 person-years in the first 6 months
Figure 1. Cause-specific crude mortality rate per 1000 person-years by duration of antiretroviral therapy. Vertical axis is on log scale. Abbreviations: ART,
antiretroviral therapy; CVD, cardiovascular disease.
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of ART to 2.4 (95% CI, 2.1–2.8) after 5 years. Rates of non-AIDS
infection also decreased with time since starting ART, from 1.8
(95% CI, 1.4–2.3) in the first 6 months to 0.9 (95% CI, 0.7–1.1)
after 5 years. By contrast, mortality from non-AIDS malignancy
increased slightly, from 1.1 (95% CI, 0.8–1.5) per 1000 person-
years in the first 6 months to 1.5 (95% CI, 1.3–1.8) after 5
years: the adjusted (for sex, year of ART start, age, CD4 and
viral load, and stratified on cohort) rate ratio was 1.04 (95% CI,
1.0–1.1) per year on ART. Rates of CVD deaths had a U-shaped
relationship with ART duration, with the lowest rates observed
between 1 and 2 years after starting ART.
CD4 measures within 6 months of death were available for
3215 patients. Median CD4 at death (median time from CD4
to death, 52 days [IQR, 24–94 days]) was 154 cells/µL (IQR,
45–344). CD4 at death was lowest for those who died of
AIDS-related causes (median, 48 [IQR, 13–140], due partly to
the use of CD4 in assigning causes of death), and highest for
those who died of CVD (median, 360 [IQR, 221–608]) and un-
natural causes (median, 340 [IQR, 150–560]) (Figure 2).
Associations of Risk Factors With Mortality According to Time
Since Starting ART
Table 3 shows associations of risk factors with cause-specific
mortality in the first year of ART. Of 1225 deaths, 168 could
not be classified and 82 were from other causes. Compared
with MSM, IDUs had higher rates of each cause of death:
rates of liver-related (HR, 18.1 [95% CI, 6.2–52.7]), substance
abuse (HR, 16.3 [95% CI, 3.7–72.3]), and heart/vascular (HR,
6.8 [95% CI, 2.2–21.0]) death were particularly elevated.
Lower mortality in women than men was mostly due to lower
rates of non-AIDS malignancy (HR, 0.3 [95% CI, 0.1–0.7]) and
liver-related (HR, 0.5 [95% CI, 0.2–1.0]) death. There was little
evidence that baseline viral load was associated with any specific
cause of death in the first year. AIDS before starting ART was
strongly associated with rates of AIDS (HR, 4.3 [95% CI, 3.6–
5.2]), non-AIDS infection (HR, 2.8 [95% CI, 1.7–4.6]), and
liver-related (HR, 1.9 [95% CI, 1.1–3.4]) death. Rates of death
from substance abuse were lower after 1999.
Table 4 shows associations of risk factors with cause-specific
mortality after the first year of ART. Of 56 756 patients alive and
in follow-up 1 year after starting ART, we excluded 9025
(15.9%) patients without 12-month measures of CD4 and
viral load (n = 47 731). Of 2326 deaths after the first year, 373
could not be classified and 223 were from other causes. CD4
at 12 months was strongly inversely associated with subsequent
rates of AIDS mortality, and also inversely associated with non-
AIDS malignancy, non-AIDS infection, and liver-related death.
Baseline CD4 was also strongly inversely associated with AIDS,
non-AIDS infection, and liver-related mortality after the first
year of ART, although the association with non-AIDS malig-
nancy was attenuated compared with the first year. Lack of
viral suppression at 12 months was associated with rates of
AIDS (HR, 3.6 [95% CI, 3.0–4.3]), non-AIDS infection (HR,
3.3 [95% CI, 2.4–4.5]), heart/vascular (HR, 1.9 [95% CI, 1.2–
3.1]), suicide (HR, 2.0 [95% CI, 1.2–3.4]), and liver-related
death (HR, 1.5 [95% CI, 1.1–2.0]). An AIDS diagnosis prior
to 12 months was associated with subsequent rates of AIDS
(HR, 2.3 [95% CI, 1.9–2.7]) and non-AIDS infection (HR, 1.5
[95% CI, 1.1–2.0]) death.
The association of presumed transmission via injection drug
use (compared with MSM) with AIDS death was stronger in
subsequent years of ART (HR, 1.5 [95% CI, 1.2–1.9]) than
the first year (HR, 1.1 [95% CI, 0.9–1.5]). IDUs also experience
higher rates of death from non-AIDS malignancy (HR, 1.7 [95%
CI, 1.2–2.5]), non-AIDS infection (HR, 4.8 [95% CI, 2.9–7.7]),
and CVD (HR, 1.9 [95% CI, 1.0–3.4]) after the first year of ART;
the strong association of injection drug use with liver-related
death was lower after (HR, 9.1 [95% CI, 5.8–14.2]) than during
the first year of ART. Compared with MSM, heterosexual trans-
mission was associated with higher rates of non-AIDS malig-
nancy (HR, 1.3 [95% CI, 1.0–1.8]), and infection-related (HR,
2.2 [95% CI, 1.3–3.5]) death. Sex differences in cause-specific
mortality rates were less pronounced after than during the
first year of ART. Age was most strongly associated with
death from CVD and non-AIDS malignancy. The effect of
age on AIDS deaths declined over time, suggesting that older
people are more vulnerable to AIDS in the first year of ART.
There was little evidence that rates of cause-specific mortality
changed over calendar time, having adjusted for other risk fac-
tors. CVD, heart/vascular, and substance abuse deaths were not
strongly related to conventional HIV risk factors. Sensitivity
analyses accounting for competing risks showed similar associ-
ations between risk factors and specific causes of mortality both
during and after the first year of ART (data not shown).
Figure 2. Latest CD4 count before death within 6 months of death.
Abbreviations: CVD, cardiovascular disease; IQR, interquartile range.
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Table 3. Adjusteda Hazard Ratios From Cox Regression Models in the First Year of Antiretroviral Therapy (N = 65121)









625 (51) 73 (6) 85 (7) 62 (5) 27 (2) 31 (3) 21 (2) 41 (3) 10 (1)
Transmission risk group
MSM 21 177 1 1 1 1 1 1 1 1
IDU 10 396 1.13 (.86–1.49) 1.46 (.66–3.21) 2.47 (1.21–5.04) 18.05 (6.18–52.72) 0.52 (.11–2.52) 6.81 (2.21–20.97) 1.32 (.33–5.31) 16.31 (3.68–72.31)
Heterosexual 26 668 0.90 (.72–1.12) 1.02 (.57–1.84) 1.26 (.66–2.38) 4.25 (1.40–12.95) 0.41 (.14–1.18) 2.53 (.86–7.42) 0.83 (.26–2.61) 2.93 (.56–15.33)
Other 6880 1.91 (1.51–2.41) 1.34 (.65–2.77) 2.66 (1.33–5.31) 6.50 (1.93–21.83) 0.62 (.19–2.00) 1.37 (.26–7.31) 1.24 (.30–5.13) 6.32 (1.18–33.68)
Sex
Male 46 798 1 1 1 1 1 1 1 1
Female 18 323 0.91 (.73–1.13) 0.29 (.12–.70) 0.82 (.46–1.45) 0.50 (.24–1.01) 1.62 (.56–4.74) 0.46 (.17–1.26) 0.17 (.02–1.39) 1.40 (.70–2.83)
Current age
(Per decade)
65 121 1.30 (1.21–1.40) 2.13 (1.76–2.59) 1.58 (1.30–1.91) 1.49 (1.16–1.92) 2.62 (1.94–3.54) 1.71 (1.24–2.36) 1.30 (.86–1.97) 1.24 (.87–1.76)
CD4 count at ART initiation, cells/µL
<50 10 210 1 1 1 1 1 1 1 1
50–99 6462 0.72 (.58–.89) 0.72 (.33–1.57) 0.58 (.29–1.15) 1.31 (.55–3.14) 0.89 (.21–3.76) 1.08 (.30–3.89) 0.18 (.02–1.50) 0.73 (.13–4.01)
100–199 13 106 0.49 (.39–.61) 0.54 (.27–1.10) 0.76 (.43–1.35) 1.33 (.61–2.93) 1.44 (.45–4.58) 1.67 (.58–4.82) 0.08 (.01–.69) 2.06 (.63–6.71)
200–349 19 971 0.28 (.21–.37) 0.51 (.25–1.02) 0.46 (.23–.92) 0.97 (.42–2.24) 1.04 (.30–3.57) 0.71 (.20–2.45) 0.34 (.10–1.16) 1.33 (.38–4.60)
≥350 15 372 0.09 (.05–.15) 0.25 (.10–.65) 0.22 (.07–.65) 0.68 (.25–1.83) 0.38 (.07–2.17) 0.64 (.16–2.58) 0.55 (.16–1.92) 2.13 (.63–7.27)
Viral load at ART initiation, log copies/mL
<5 37 757 1 1 1 1 1 1 1 1
≥5 27 364 1.01 (.86–1.20) 0.91 (.56–1.48) 1.48 (.93–2.36) 0.65 (.38–1.12) 1.09 (.49–2.41) 1.24 (.59–2.63) 1.25 (.51–3.10) 0.98 (.51–1.87)
AIDS at ART initiation
No 50 919 1 1 1 1 1 1 1 1
Yes 14 202 4.31 (3.55–5.23) 0.68 (.37–1.24) 2.84 (1.74–4.63) 1.90 (1.06–3.41) 1.18 (.47–2.98) 1.22 (.53–2.81) 0.51 (.15–1.73) 0.89 (.35–2.27)
Period of HAART initiation
1996–1999 19 720 1 1 1 1 1 1 1 1
2000–2003 22 528 1.00 (.82–1.20) 0.77 (.43–1.41) 1.72 (.93–3.20) 0.91 (.48–1.72) 1.18 (.46–3.02) 1.02 (.44–2.40) 0.95 (.31–2.87) 0.26 (.10–.63)
2004 onward 22 873 0.83 (.67–1.03) 0.98 (.55–1.75) 1.88 (1.00–3.53) 1.08 (.56–2.11) 0.58 (.19–1.75) 0.88 (.35–2.22) 1.40 (.49–4.04) 0.43 (.19–.99)
Data are presented as hazard ratios (95% confidence intervals).
Abbreviations: ART, antiretroviral therapy; CVD, cardiovascular disease; HAART, highly active antiretroviral therapy; IDU, injection drug user; MSM, men who have sex with men.
a Adjusted for transmission risk, sex, age, Viral Load, CD4, AIDS, year of ART initiation, stratified by cohort.
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Table 4. Adjusteda Hazard Ratios From Cox Regression Models After the First Year of Antiretroviral Therapy (n = 47 731)











No. (%) of deaths 643 (28) 326 (14) 178 (8) 184 (8) 106 (5) 78 (3) 64 (3) 111 (5) 40 (2)
Transmission risk group
MSM 16 227 1 1 1 1 1 1 1 1 1
IDU 7003 1.53 (1.22–1.91) 1.71 (1.19–2.45) 4.76 (2.94–7.71) 9.05 (5.75–14.24) 1.88 (1.03–3.40) 4.54 (2.32–8.86) 1.34 (.68–2.64) 5.87 (3.14–10.97) 2.68 (1.19–6.04)
Heterosexual 19 737 0.76 (.60–.96) 1.34 (1.01–1.77) 2.16 (1.33–3.51) 0.81 (.45–1.46) 0.82 (.47–1.41) 1.30 (.66–2.56) 0.68 (.33–1.41) 1.47 (.70–3.08) 0.35 (.11–1.07)
Other 4764 1.27 (.98–1.64) 1.14 (.76–1.72) 3.02 (1.74–5.25) 2.22 (1.20–4.10) 1.81 (1.01–3.24) 2.11 (.96–4.65) 0.46 (.15–1.40) 2.45 (1.14–5.24) 1.71 (.64–4.54)
Sex
Male 34 468 1 1 1 1 1 1 1 1 1
Female 13 263 1.08 (.88–1.32) 0.56 (.40–.79) 0.70 (.47–1.04) 0.84 (.56–1.25) 0.89 (.51–1.56) 0.85 (.47–1.54) 0.67 (.31–1.46) 0.86 (.52–1.42) 1.01 (.41–2.49)
Current age (per
decade)
47 731 1.18 (1.09–1.28) 2.08 (1.90–2.29) 1.46 (1.26–1.70) 1.55 (1.31–1.83) 2.12 (1.80–2.51) 1.87 (1.51–2.31) 1.12 (.86–1.46) 1.16 (.93–1.45) 1.23 (.88–1.71)
CD4 count at 12 mo, cells/µL
<200 9020 1 1 1 1 1 1 1 1 1
200–349 12 794 0.38 (.31–.46) 0.76 (.57–1.01) 0.62 (.43–.90) 0.54 (.37–.79) 0.95 (.55–1.65) 0.92 (.51–1.65) 1.93 (.84–4.39) 0.47 (.26–.83) 1.25 (.50–3.10)
350–499 11 526 0.18 (.14–.24) 0.63 (.45–.87) 0.47 (.30–.74) 0.44 (.28–.69) 0.76 (.41–1.43) 0.59 (.29–1.19) 1.20 (.48–3.00) 0.78 (.46–1.34) 1.33 (.51–3.44)
500–749 10 028 0.15 (.10–.21) 0.59 (.41–.85) 0.34 (.19–.59) 0.36 (.22–.60) 1.08 (.58–2.00) 0.72 (.35–1.45) 1.32 (.53–3.29) 1.04 (.61–1.76) 0.66 (.21–2.13)
≥750 4363 0.18 (.11–.29) 0.59 (.36–.95) 0.59 (.31–1.12) 0.35 (.18–.70) 1.34 (.64–2.79) 0.45 (.15–1.34) 2.07 (.78–5.50) 0.45 (.18–1.10) 1.10 (.31–3.91)
Viral suppression at 12 mo
Yes 34 695 1 1 1 1 1 1 1 1 1
No 13 036 3.61 (3.03–4.30) 1.07 (.83–1.38) 3.26 (2.37–4.50) 1.46 (1.07–1.99) 0.94 (.59–1.52) 1.93 (1.19–3.14) 2.01 (1.18–3.42) 1.36 (.91–2.03) 1.31 (.67–2.57)
AIDS at 12 mo
No 36 111 1 1 1 1 1 1 1 1 1
Yes 11 620 2.28 (1.93–2.69) 1.26 (.99–1.61) 1.47 (1.06–2.04) 1.25 (.90–1.73) 1.12 (.71–1.76) 0.78 (.45–1.35) 0.44 (.20–.96) 1.05 (.66–1.68) 1.04 (.48–2.22)
Period of HAART initiation
1996–1999 14 805 1 1 1 1 1 1 1 1 1
2000–2003 17 327 0.88 (.74–1.06) 0.74 (.57–.97) 1.44 (1.02–2.02) 0.67 (.47–.95) 0.86 (.54–1.39) 0.75 (.44–1.28) 0.77 (.43–1.40) 0.86 (.56–1.32) 0.57 (.27–1.21)
2004 onward 15 599 1.04 (.78–1.37) 1.04 (.71–1.50) 0.91 (.47–1.75) 0.56 (.30–1.07) 1.61 (.82–3.16) 0.79 (.34–1.81) 0.85 (.33–2.19) 0.58 (.27–1.23) 0.64 (.17–2.38)
CD4 count at ART initiationb, cells/µL
<50 7622 1 1 1 1 1 1 1 1 1
50–99 4786 0.73 (.58–.93) 1.18 (.82–1.70) 0.74 (.44–1.23) 1.04 (.63–1.72) 0.73 (.33–1.62) 0.68 (.29–1.60) 0.77 (.22–2.67) 1.54 (.74–3.21) 1.61 (.46–5.63)
100–199 9646 0.60 (.48–.75) 0.91 (.64–1.31) 0.78 (.50–1.21) 0.82 (.51–1.31) 1.19 (.63–2.25) 0.81 (.40–1.65) 0.72 (.25–2.07) 1.28 (.64–2.56) 1.33 (.41–4.31)
200–349 14 551 0.39 (.30–.50) 0.75 (.52–1.08) 0.53 (.33–.87) 0.77 (.48–1.24) 1.12 (.59–2.14) 0.50 (.24–1.08) 1.11 (.44–2.84) 1.35 (.68–2.66) 1.17 (.36–3.84)
350–499 6470 0.24 (.17–.34) 0.67 (.42–1.06) 0.46 (.25–.85) 0.80 (.46–1.38) 0.79 (.34–1.82) 0.47 (.19–1.18) 1.44 (.53–3.89) 1.47 (.68–3.17) 1.14 (.30–4.26)
≥500 4656 0.19 (.12–.30) 0.98 (.61–1.56) 0.59 (.31–1.12) 0.38 (.18–.82) 1.47 (.67–3.25) 0.90 (.38–2.13) 2.10 (.77–5.68) 2.04 (.94–4.43) 1.52 (.40–5.80)
Data are presented as hazard ratios (95% confidence intervals).
Abbreviations: ART, antiretroviral therapy; CVD, cardiovascular disease; HAART, highly active antiretroviral therapy; IDU, injection drug user; MSM, men who have sex with men.
a Adjusted for transmission risk, sex, age, 12-month Viral Load, CD4, and AIDS status, and year of ART initiation, stratified by cohort.
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DISCUSSION
Based on data from a large, multinational cohort collaboration
in which causes of death were classified using standardized pro-
cedures, both the distribution of causes of death and their asso-
ciations with patient characteristics differed substantially with
time since starting ART.Whereas rates of AIDS death decreased
substantially with time since starting ART, rates of non-AIDS
malignancy death increased. Higher mortality in men than
women during the first year of ART was mostly driven by
higher rates of non-AIDS malignancy and liver-related death:
between-sex differences decreased with increasing time on
ART. Associations with age were strongest for death from
CVD, heart/vascular causes, and malignancy. In these data,
46% of patients started ART with a CD4 count <200 cells/µL.
There was a persistent role of CD4 count at baseline and 12
months after starting ART in predicting rates of death from
AIDS, non-AIDS infection, and non-AIDS malignancy. Lack
of viral suppression on ART was strongly associated with
death from AIDS and non-AIDS infection, and was also associ-
ated with a number of other causes of death. Patients with pre-
sumed transmission via injection drug use had persistently high
rates of liver-related death, and persistently higher rates of both
AIDS and other non-AIDS causes of death.
There were several strengths and limitations to this study. Pa-
tients were from diverse populations in clinical care across Eu-
rope and North America [18]. We compiled a dataset with
follow-up on >65 000 patients who experienced >4000 deaths.
Thanks to a team of experienced HIV clinicians using standard-
ized procedures, 3574 (84%) deaths were classified as due to
specific causes [19]. Disagreements were carefully resolved via
panel discussion. Coding was done retrospectively and without
complete patient histories, so there will be some misclassifica-
tion. Classification of cause of death based on autopsy remains
the gold standard: clinical classifications may not correlate well
with classifications from autopsy reports [20, 21].However rates
of autopsy are diminishing over time [8].Not all deaths could be
classified, which will bias estimates of cause-specific mortality
rates downward. Application of a stepwise algorithm to code
deaths as AIDS or non-AIDS related could allow broad coding
of deaths where specific cause is missing [22]. Data on
established risk factors for chronic diseases were not available
for all patients and therefore we were unable to estimate their
contributions to cause-specific mortality. For example, we do
not know whether patients smoke tobacco or abuse alcohol.
Some patients classified in the “other” transmission group are
likely to have had transmission via injection drug use.
Data on ART adherence was not available: this information
might provide further insights into patterns of cause-specific
mortality but is captured to an extent by viral suppression at
12 months.
The EuroSIDA cohort [23] found little evidence for increased
rates of all-cause or non-AIDS-related deaths with long-term
cumulative combination ART exposure. By contrast, we found
evidence that deaths from non-AIDS malignancy increased
with time since ART. An Italian study showed that malignan-
cies, infections, and end-stage liver disease were leading causes
of death among PLWH [4]. Studies of the HIV-infected popu-
lation in France and Switzerland have shown the increasing im-
portance of non-AIDS malignancies, liver disease, and CVD
over calendar time [8, 15, 24] and this was seen for non-AIDS
malignancies in our previous work [9]. Prevalence of tobacco
smoking is known to be higher among PLWH and may contrib-
ute substantially to rates of death from CVD and some cancers
[25, 26]. Other established chronic disease risk factors may also
be more prevalent in HIV-infected populations.
As patients become increasingly treatment experienced,
monitoring patterns of causes of death over longer durations
of ART will be important for optimizing management of
PLWH, many of whom develop comorbidities [27]. Under-
standing changes in cause-specific deaths with ART duration
can help direct appropriate screening procedures, risk assess-
ment, and preventive treatment for PLWH. The well-known
high early mortality from AIDS [28, 29] is best addressed by
more timely HIV diagnosis and earlier treatment [30]. The per-
sistent role of lower CD4 counts and lack of viral suppression in
predicting both AIDS and non-AIDS death after the first year of
ART emphasizes the importance of maintaining adherence to
therapy and ensuring patients are switched from failing regi-
mens. The association of injection drug use with AIDS deaths
was stronger after the first year, which may suggest a role of
nonadherence to ART. Mortality later in the course of treatment
is increasingly due to non-AIDS malignancies, liver disease, and
CVD, whose occurrence also increases with age in HIV-
uninfected individuals. Continuing study of cause-specific mor-
tality is required to clarify whether such mortality arises from
effects of ART, prolonged exposure to the virus, consequences
of restoration of CD4 counts after severe immunosuppression,
or whether such mortality mainly reflects aging and non-HIV
risk factors. Large studies would be required to compare age-
standardized mortality rates and risk factors for HIV-infected
and -uninfected populations, to quantify excess cause-specific
mortality among HIV-infected individuals once known risk
factors are accounted for [27].
To better differentiate mortality risks for those on ART, it will
be important to monitor “non-HIV” biomarkers as well as CD4
and viral load. The VACS Index, which includes markers for
anemia, liver injury, renal insufficiency, and chronic viral hep-
atitis as well as factors prognostic for HIV progression, can
identify patients at high risk of mortality [31, 32]. Better treat-
ment of hepatitis B and C coinfection [33, 34], interventions to
decrease harm from alcohol or illicit drug abuse, and smoking
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cessation programs [35] potentially offer opportunities to de-
crease the risk of diseases that are prevalent among PLWH.
US treatment guidelines recommend screening for hepatitis C
before starting ART for all PLWH, but annual screening is
only recommended for certain subgroups [36]. The European
AIDS Clinical Society guidelines recommends screening for cer-
tain non-AIDS malignancies in subgroups of PLWH, annual
screening for hepatitis C, and management of CVD risk as
part of routine clinical care [37]. However, guidelines are not
always followed, and improved management of chronic diseases
will require close collaboration between specialists.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online
(http://cid.oxfordjournals.org). Supplementary materials consist of data
provided by the author that are published to benefit the reader. The posted
materials are not copyedited. The contents of all supplementary data are the
sole responsibility of the authors. Questions or messages regarding errors
should be addressed to the author.
Notes
Acknowledgments. We thank all patients, doctors, and study nurses as-
sociated with the participating cohort studies.
Author contributions. M. T. M. and J. A. C. S. conceived the idea; S. M. I.
performed statistical analyses and wrote the first draft of the paper; and all
authors contributed to study design, collection of data, data interpretation,
and writing the paper, and approved the final version. S. M. I. had full access
to the data and acts as guarantor for the paper.
Financial support. This work was supported by the UK Medical Re-
search Council and the Department for International Development (grants
G0700820 and MR/J002380/1). J. S. was supported by National Institute for
Health Research (NIHR) Senior Investigator Award NF-SI-0611-10168.
Sources of funding of individual cohorts include the Agence Nationale
de Recherche sur le SIDA et les hépatites virales; the Institut National de
la Santé et de la Recherche Médicale; the French, Italian and Spanish Min-
istries of Health; the Swiss National Science Foundation (grant
33CS30_134277); the Ministry of Science and Innovation and the “Spanish
Network for AIDS Research (RIS; ISCIII-RETIC RD06/006); the Stichting
HIV Monitoring; the European Commission (EuroCoord grant 260694);
the British Columbia and Alberta governments; the National Institutes of
Health (NIH) [UW Center for AIDS Research (CFAR)] (NIH grant P30
AI027757); University of Alabama at Birmingham (UAB) CFAR (NIH
grant P30-AI027767); the Vanderbilt-Meharry CFAR (NIH grant P30
AI54999); the National Institute on Alcohol Abuse and Alcoholism (U10-
AA13566, U24-AA020794); the US Department of Veterans Affairs; the Mi-
chael Smith Foundation for Health Research; the Canadian Institutes of
Health Research; the VHA Office of Research and Development; and unre-
stricted grants from Abbott, Gilead, Tibotec-Upjohn, ViiV Healthcare,
MSD, GlaxoSmithKline, Pfizer, Bristol-Myers Squibb, Roche, and Boeh-
ringer-Ingelheim.
Potential conflicts of interest. M. S. S. has grants fromMerck, BIPI, BMS,
Gilead, and Janssen. D. M. has a grant and has support for travel to meetings
from the UK Medical Research Council (MRC). T. R. S. has received grant
money from the UK MRC and has grants pending from Pfizer, BMS, and
Virco. H. M. C. has a grant from the NIH and grants pending from NIH,
Agency for Healthcare Research and Quality (AHRQ), Centers for Disease
Control and Prevention, and Health Resources and Services Administration
(HRSA), and received payment for developing educational materials for
WebMD. R. T. has received payment for service on speakers’ bureaus and
travel/meeting expenses from Bristol-Myers Squibb, Viiv Healthcare, Gilead
Sciences, Janssen-Cilag, and Abbvie. P. R. is a board member for Gilead
and Janssen, has grants pending from Gilead, Viiv Healthcare, Merck, Jans-
sen, and Bristol-Myers Squibb, and had travel/meeting expenses from Gilead
and Janssen. A. D. M. is a board member for BMS, Abbvie, Gilead, Janssen,
and MSD, and has grants pending from MSD, Janssen, and Gilead. M. J. M.
has consulted for BMS, Gilead, andMerck and has grants pending from BMS,
Definicare, and Pfizer. M. C. has consulted for BMS, Boehringer-Ingelheim,
Gilead, MSD, and Janssen-Cilag, has grants pending from BMS, Gilead, and
MSD, and has received payment for service on speakers’ bureaus from Gilead
and travel/meeting expenses from Boehringer-Ingelheim, BMS, and
Gilead. M. J. G. is a board member for Abbvie, Gilead, Merck, Janssen,
BMS, and ViiV Healthcare. G. F. is a board member for BMS, Gilead,
Merck, and Janssen, has grants pending from AbbVie, and has received pay-
ment for service on speakers bureaus fromAbbVie, BMS, Gilead, Janssen, and
Merck. J. A. C. S. has received payment for development of educational pre-
sentations from Gilead. A. M. has received payment for consultancy from
Wragge and Co LLP. S. A. is a board member for Janssen-Cilag, and has re-
ceived payment for service on speakers’ bureaus fromGilead, and travel/meet-
ing expenses from Janssen-Cilag, Gilead, and Abbott. All other authors report
no potential conflicts.
All authors have submitted the ICMJE Form for Disclosure of Potential
Conflicts of Interest. Conflicts that the editors consider relevant to the con-
tent of the manuscript have been disclosed
References
1. MayM, Gompels M, Delpech V, et al. Impact of late diagnosis and treat-
ment on life expectancy in people with HIV-1: UK Collaborative HIV
Cohort (UK CHIC) Study. BMJ 2011; 343:d6016.
2. Nakagawa F, Lodwick RK, Smith CJ, et al. Projected life expectancy of
people with HIV according to timing of diagnosis. AIDS 2012;
26:335–43.
3. May MT, Ingle SM. Life expectancy of HIV-positive adults: a review. Sex
Health 2011; 8:526–33.
4. Leone S, Gregis G, Quinzan G, et al. Causes of death and risk factors
among HIV-infected persons in the HAART era: analysis of a large
urban cohort. Infection 2011; 39:13–20.
5. Galli L, Spagnuolo V, Salpietro S, et al. Mortality of HIV-infected pa-
tients with or without cancer: comparison with the general population
in Italy. Antivir Ther 2012; 17:447–58.
6. Aldaz P, Moreno-Iribas C, Egues N, et al. Mortality by causes in HIV-
infected adults: comparison with the general population. BMC Public
Health 2011; 11:300.
7. Lohse N, Gerstoft J, Kronborg G, et al. Comorbidity acquired before
HIV diagnosis and mortality in persons infected and uninfected with
HIV: a Danish population-based cohort study. J Acquir Immune
Defic Syndr 2011; 57:334–9.
8. Weber R, Ruppik M, Rickenbach M, et al. Decreasing mortality and
changing patterns of causes of death in the Swiss HIV Cohort Study.
HIV Med 2013; 14:195–207.
9. Gill MJ, May M, Lewden C, et al. Causes of death in HIV-1-infected
patients treated with antiretroviral therapy, 1996–2006: collaborative
analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50:1387–96.
10. Pakkala S, Chen Z, Rimland D, et al. Human immunodeficiency virus-
associated lung cancer in the era of highly active antiretroviral therapy.
Cancer 2012; 118:164–72.
11. Simard EP, Pfeiffer RM, Engels EA. Mortality due to cancer among peo-
ple with AIDS: a novel approach using registry-linkage data and popu-
lation attributable risk methods. AIDS 2012; 26:1311–8.
12. Deeken JF, Tjen-A-Looi A, Rudek MA, et al. The rising challenge of
non-AIDS-defining cancers in HIV-infected patients. Clin Infect Dis
2012; 55:1228–35.
13. May MT, Ingle SM, Costagliola D, et al. Cohort profile: Antiretroviral
Therapy Cohort Collaboration (ART-CC). Int J Epidemiol 2013. Ad-
vance Access published 18 April 2013. doi: 10.1093/ije/dyt010.
296 • CID 2014:59 (15 July) • HIV/AIDS
 at Instituto de Salud C








14. The CoDe (“Coding of Death in HIV”) Project. Available at: http://www.
cphiv.dk/code/about/tabid/64/default.aspx. Accessed 29 May 2013.
15. Lewden C, May T, Rosenthal E, et al. Changes in causes of death among
adults infected by HIV between 2000 and 2005: the “Mortalite 2000 and
2005” surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic
Syndr 2008; 48:590–8.
16. Centers for Disease Control and Prevention. 1993 revised classification
system for HIV infection and expanded surveillance case definition for
AIDS among adolescents and adults. MMWR Recomm Rep 1992;
41:1–19.
17. Fine JP, Gray RJ. A proportional hazards model for the subdistribution
of a competing risk. Journal of the American Statistical Association
1999; 94:496–509.
18. May MT, Hogg RS, Justice AC, et al. Heterogeneity in outcomes of treat-
ed HIV-positive patients in Europe and North America: relation with
patient and cohort characteristics. Int J Epidemiol 2012; 41:1807–20.
19. Kowalska JD, Friis-Moller N, Kirk O, et al. The Coding Causes of Death
in HIV (CoDe) Project: initial results and evaluation of methodology.
Epidemiology 2011; 22:516–23.
20. Roulson J, Benbow EW, Hasleton PS. Discrepancies between clinical
and autopsy diagnosis and the value of post mortem histology; a
meta-analysis and review. Histopathology 2005; 47:551–9.
21. Cox JA, Lukande RL, Lucas S, Nelson AM, VanMarck E, Colebunders R.
Autopsy causes of death in HIV-positive individuals in sub-Saharan Af-
rica and correlation with clinical diagnoses. AIDS Rev 2010; 12:183–94.
22. Kowalska JD, Mocroft A, Ledergerber B, et al. A standardized algorithm
for determining the underlying cause of death in HIV infection as AIDS
or non-AIDS related: results from the EuroSIDA study. HIV Clin Trials
2011; 12:109–17.
23. Kowalska JD, Reekie J, Mocroft A, et al. Long-term exposure to combi-
nation antiretroviral therapy and risk of death from specific causes: no
evidence for any previously unidentified increased risk due to antiretro-
viral therapy. AIDS 2012; 26:315–23.
24. Lewden C, Salmon D, Morlat P, et al. Causes of death among human
immunodeficiency virus (HIV)-infected adults in the era of potent an-
tiretroviral therapy: emerging role of hepatitis and cancers, persistent
role of AIDS. Int J Epidemiol 2005; 34:121–30.
25. Lifson AR, Neuhaus J, Arribas JR, et al. Smoking-related health risks
among persons with HIV in the Strategies for Management of Antire-
troviral Therapy clinical trial. Am J Public Health 2010; 100:1896–903.
26. Horvath KJ, Eastman M, Prosser R, Goodroad B, Worthington L. Ad-
dressing smoking during medical visits: patients with human immuno-
deficiency virus. Am J Prev Med 2012; 43(5 suppl 3): S214–21.
27. Schouten J, Wit FW, Stolte IG, et al. Comorbidity and ageing in HIV-1
infection: the AGEhIV Cohort Study. In: 19th International AIDS Con-
ference, Washington D.C., 2012. Abstract THAB0205.
28. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline
CD4 cell count and viral load after initiating triple-drug therapy. JAMA
2001; 286:2568–77.
29. Palella FJ Jr, Deloria-Knoll M, Chmiel JS, et al. Survival benefit of ini-
tiating antiretroviral therapy in HIV-infected persons in different CD4+
cell strata. Ann Intern Med 2003; 138:620–6.
30. Moyer VA; US Preventive Service Task Force. Screening for HIV: U.S.
Preventive Services Task Force recommendation statement. Ann Intern
Med 2013; 159:51–60.
31. Tate JP, Justice AC, Hughes MD, et al. An internationally generalizable
risk index for mortality after one year of antiretroviral therapy. AIDS
2013; 27:563–72.
32. Justice AC, McGinnis KA, Skanderson M, et al. Towards a combined
prognostic index for survival in HIV infection: the role of ‘non-HIV’
biomarkers. HIV Med 2010; 11:143–51.
33. Thompson AJ, Locarnini S. Direct-acting antiviral agents for the treat-
ment of HCV. Antivir Ther 2012; 17(6 pt B): 1105–7.
34. Munteanu DI, Rockstroh J. New agents for the treatment of hepatitis
C in patients co-infected with HIV. Ther Adv Infect Dis 2013;
1:71–80.
35. Petoumenos K, Worm S, Reiss P, et al. Rates of cardiovascular disease
following smoking cessation in patients with HIV infection: results from
the D:A:D study. HIV Med 2011; 12:412–21.
36. US Department of Health and Human Services. Guidelines for the
use of antiretroviral agents in HIV-1-infected adults and adolescents:
Panel on Antiretroviral Guidelines for Adults and Adolescents.
Department of Health and Human Services, 2012. Available at: http://
aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 12
August 2013.
37. European AIDS Clinical Society Guidelines version 6.1, November




List of contributing cohorts. Sixteen cohorts contributed data
on causes of death: the French Hospital Database on HIV
(FHDH) and the Aquitaine Cohort (France), the AIDS Therapy
Evaluation project Netherlands (ATHENA), Italian Cohort of
Antiretroviral-Naïve Patients (ICONA), the Swiss HIV Cohort
Study (SHCS), the Köln/Bonn Cohort (Germany), the EuroSIDA
study (33 countries in Europe and Argentina), the HAART
Observational Medical Evaluation and Research (HOMER)
and the Southern Alberta Clinic Cohort (Canada), the Proyecto
para la Informatizacion del Seguimiento Clinico-epidemiologico
de la Infeccion por HIV y SIDA (PISCIS), Cohorte de la Red de
Investigación en Sida (CoRIS) cohort and the VACH cohort
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